Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients.
10.1007/s11684-021-0843-8
- Author:
Lei FAN
1
;
Li WANG
1
;
Lei CAO
1
;
Huayuan ZHU
1
;
Wei XU
2
;
Jianyong LI
3
Author Information
1. Department of Hematology, Pukou CLL Center, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
2. Department of Hematology, Pukou CLL Center, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. xuwei0484@jsph.org.cn.
3. Department of Hematology, Pukou CLL Center, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. lijianyonglm@126.com.
- Publication Type:Journal Article
- Keywords:
CAR-T cell therapy;
cytokine release syndrome;
dose-limiting toxicity;
refractory diffuse large B-cell lymphoma
- MeSH:
Antigens, CD19/adverse effects*;
China;
Humans;
Lymphoma, Large B-Cell, Diffuse/therapy*;
Receptors, Chimeric Antigen;
T-Lymphocytes
- From:
Frontiers of Medicine
2022;16(2):285-294
- CountryChina
- Language:English
-
Abstract:
Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cell malignancies. A single-center phase I dose-escalation study was conducted to evaluate the safety and efficacy of T cells transduced with CBM.CD19 CAR, a second-generation anti-CD19 CAR bearing 4-1BB costimulatory molecule, for the treatment of patients with refractory diffuse large B-cell lymphoma (DLBCL). Ten heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell (C-CAR011) treatment. The overall response rate was 20% and 50% at 4 and 12 weeks after the infusion of C-CAR011, respectively, and the disease control rate was 60% at 12 weeks after infusion. Treatment-emergent adverse events occurred in all patients. The incidence of cytokine release syndrome in all grades and grade ⩾ 3 was 90% and 0, respectively, which is consistent with the safety profile of axicabtagene ciloleucel and tisagenlecleucel. Neurotoxicity or other dose-limiting toxicities was not observed in any dose cohort of C-CAR011 therapy. Antitumor efficacy was apparent across dose cohorts. Therefore, C-CAR011 is a safe and effective therapeutic option for Chinese patients with refractory DLBCL, and further large-scale clinical trials are warranted.
